(NASDAQ: APVO) Aptevo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.
Aptevo Therapeutics's earnings in 2025 is -$24,025,000.On average, 1 Wall Street analyst forecast APVO's earnings for 2025 to be -$1,041,612,422, with the lowest APVO earnings forecast at -$1,041,612,422, and the highest APVO earnings forecast at -$1,041,612,422. On average, 1 Wall Street analyst forecast APVO's earnings for 2026 to be -$952,838,636, with the lowest APVO earnings forecast at -$952,838,636, and the highest APVO earnings forecast at -$952,838,636.
In 2027, APVO is forecast to generate -$659,556,351 in earnings, with the lowest earnings forecast at -$659,556,351 and the highest earnings forecast at -$659,556,351.